Tesamorelin: Growth Hormone-Releasing Agent with Clinical Evidence

EXOMA Scientific Team · Publicado el 13 de abril de 2026 · Actualizado el 17 de agosto de 2026

Tesamorelin: GHRH analog with FDA approval. Mechanism of action, clinical evidence in lipodystrophy, comparison with CJC-1295 and Ipamorelin.

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) composed of the 44 amino acids of GHRH(1-44) with one modification: the addition of a trans-3-hexenoic acid at the N-terminus. This modification confers greater stability and resistance to degradation by dipeptidyl peptidase IV (DPP-IV).

Pharmacological Data

• Generic name: Tesamorelin acetate
• Manufacturer: Theratechnologies Inc.
• FDA approval: 2010
• Indication: Reduction of visceral fat in HIV-associated lipodystrophy

Mechanism of Action

Tesamorelin acts on the somatotropic axis through:

1. Binding to GHRH-R: Binds to the GHRH receptor on the somatotroph cells of the anterior pituitary
2. Activation of Gs: Estimulación de adenilato ciclasa → aumento de cAMP
3. Pulsatile GH release: Stimulates the physiological secretion of growth hormone
4. Increase in IGF-1: La GH liberada estimula la producción hepática de IGF-1
5. Physiological feedback: Keeps the negative feedback axis intact

Advantage over Exogenous GH

Unlike direct administration of GH:

• Preserves the natural pulsatility of GH secretion
• Does not suppress endogenous production
• Lower risk of supraphysiological effects
• Maintains negative feedback by somatostatin

Clinical Evidence

Pivotal Studies in Lipodystrophy

LIPO-010 and LIPO-011 studies (Phase III):

• Design: Multicenter, double-blind, placebo-controlled
• N: 806 patients with HIV-associated lipodystrophy
• Duration: 26 weeks
• Results:
• Reduction of 15.4% in visceral fat (VAT) vs. increase in the placebo group
• 81% increase in IGF-1 levels
• Improvement in triglyceride profile
• Reported improvement in body image

52-week extension study:

• Maintenance of VAT reduction
• Favorable safety profile
• No significant tachyphylaxis

Research in Body Composition

Additional studies have evaluated:

• Reduction of hepatic fat: Significant reduction of steatosis in clinical models
• Lipid profile: Improvement in triglyceride and cholesterol levels
• Cognitive function: Preliminary studies in mild cognitive impairment (MCI) show improvement in verbal memory and executive function

Cognition Study (2012)

Published in Archives of Neurology:

• 61 adults with MCI or subjective cognition
• 20 weeks of treatment
• Significant improvements in episodic verbal memory
• Increase in cortical volume in temporoparietal regions

Comparison with Other GH Secretagogues

CJC-1295

CJC-1295 is another GHRH(1-29) analog with two variants:

• Without DAC: Half-life ~30 min, more similar to tesamorelin
• With DAC: Drug Affinity Complex that extends half-life to 8+ days through albumin binding

Ipamorelin

Ipamorelin acts through a different pathway:

• Selective agonist of the GH secretagogue receptor (GHS-R/ghrelin receptor)
• High selectivity for GH without affecting cortisol, prolactin or aldosterone
• Synergistic action with GHRH analogs

GHRH + GHRP synergy

The combination of a GHRH analog (such as tesamorelin or CJC-1295) with a GHRP (such as ipamorelin) produces a release of GH synergistic (non-additive), since they act through different receptors and signaling pathways.

Pharmacokinetics

• SC absorption: Tmax of 0.15-0.23 hours
• Half-life: 26-38 minutes
• GH peak: 30-60 minutes post-injection
• Duration of effect: 2-4 hours of GH elevation
• Metabolism: Peripheral proteolysis

Safety Profile

In the clinical studies, the most common adverse effects were:

• Injection-site reactions (8.5%)
• Arthralgia (5.3%)
• Peripheral edema (4.5%)
• Myalgia (3.3%)
• Paresthesias (2.5%)

Conclusion

Tesamorelin is the only GH secretagogue with regulatory approval, backed by robust phase III clinical trials. Its mechanism of physiological stimulation of GH secretion distinguishes it from exogenous administration of growth hormone, and its combination with other secretagogues such as CJC-1295 and Ipamorelin represents an active area of research.

Available at Exoma Peptides with certified purity and COA included.

References

Material for research use only. The following primary sources support the scientific claims of this article:

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID 18057338.
2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID 20554713.

Products available at EXOMA

• Tesamorelin